Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Medical School to Use High Throughput Genomics' qNPA Technology

NEW YORK (GenomeWeb News) – Harvard Medical School researchers will use High Throughput Genomics’ technology to develop an assay that can measure the expression of miRNA precursors, mature microRNAs, and regulated RNA.
 
Tucson, Ariz.-based HTG said today that it will collaborate with the Harvard Catalyst Laboratory for Innovative Translational Technologies at Harvard Medical School to create the biogenesis assay.
 
Under the agreement, the lab will use HTG’s quantitative Nuclease Protection Assay technology, which the company said allows researchers to “test any sample, including fixed tissues, without RNA extraction or target amplification.” The qNPA technology is used to carry out quantitative, multiplexed gene-based drug programs, including target validation, HTS lead optimization, metabolism, toxicology, and clinical development.
 
Financial terms of the agreement were not released.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.